RU2019124875A - Схемы дозирования и лекарственные формы для направленного ингибирования tgf-b - Google Patents
Схемы дозирования и лекарственные формы для направленного ингибирования tgf-b Download PDFInfo
- Publication number
- RU2019124875A RU2019124875A RU2019124875A RU2019124875A RU2019124875A RU 2019124875 A RU2019124875 A RU 2019124875A RU 2019124875 A RU2019124875 A RU 2019124875A RU 2019124875 A RU2019124875 A RU 2019124875A RU 2019124875 A RU2019124875 A RU 2019124875A
- Authority
- RU
- Russia
- Prior art keywords
- sheet
- substrate
- electrically conductive
- shaped
- conductive metal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Endoscopes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443698P | 2017-01-07 | 2017-01-07 | |
| US62/443,698 | 2017-01-07 | ||
| US201762581978P | 2017-11-06 | 2017-11-06 | |
| US62/581,978 | 2017-11-06 | ||
| PCT/US2018/012604 WO2018129331A1 (en) | 2017-01-07 | 2018-01-05 | Dosing regimens and dosage forms for targeted tgf-b inhibition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019124875A true RU2019124875A (ru) | 2021-02-08 |
| RU2019124875A3 RU2019124875A3 (enExample) | 2021-07-08 |
Family
ID=62791283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019124875A RU2019124875A (ru) | 2017-01-07 | 2018-01-05 | Схемы дозирования и лекарственные формы для направленного ингибирования tgf-b |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20190330375A1 (enExample) |
| EP (1) | EP3565599A4 (enExample) |
| JP (1) | JP2020514290A (enExample) |
| KR (1) | KR20190102059A (enExample) |
| CN (1) | CN110198738A (enExample) |
| AU (1) | AU2018205233A1 (enExample) |
| BR (1) | BR112019013924A2 (enExample) |
| CA (1) | CA3048646A1 (enExample) |
| CL (1) | CL2019001871A1 (enExample) |
| IL (1) | IL267856A (enExample) |
| MX (1) | MX2019008001A (enExample) |
| PH (1) | PH12019501574A1 (enExample) |
| RU (1) | RU2019124875A (enExample) |
| SG (1) | SG11201906157YA (enExample) |
| WO (1) | WO2018129331A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1225740A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma Inc. | TGF-β受体II型变体及其用途 |
| CN116327952A (zh) | 2015-08-04 | 2023-06-27 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
| EP3628049B1 (en) | 2017-05-04 | 2023-05-10 | Acceleron Pharma Inc. | Tgf-beta receptor type ii fusion proteins and uses thereof |
| TW202019959A (zh) * | 2018-06-22 | 2020-06-01 | 德商馬克專利公司 | 用於治療膽道癌的標靶性tgf-b抑制之給藥方案 |
| TW202019405A (zh) * | 2018-07-02 | 2020-06-01 | 德商馬克專利公司 | 用於治療晚期非小細胞肺癌之標靶性TGF-β抑制之組合療法 |
| CN120775065A (zh) | 2018-07-09 | 2025-10-14 | 普瑞赛格恩公司 | 融合构建体及其使用方法 |
| JP7436477B2 (ja) * | 2018-11-09 | 2024-02-21 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | ＴＧＦ－β受容体融合タンパク質医薬組成物およびその使用 |
| MX2021009175A (es) | 2019-01-30 | 2021-09-14 | Scholar Rock Inc | Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos. |
| EP3929215A4 (en) * | 2019-06-10 | 2022-06-22 | Shandong Boan Biotechnology Co., Ltd. | BIFUNCTIONAL FUSION PROTEIN AGAINST PDL1 AND TGF? AND ITS USE |
| CN112574314A (zh) * | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 一种融合蛋白及其应用 |
| AU2020370370A1 (en) * | 2019-10-24 | 2022-05-05 | Amgen Inc. | Systems and approaches for drug delivery |
| IL292613A (en) * | 2019-11-01 | 2022-07-01 | Ares Trading Sa | Combined inhibition of pd-1, tgfβ and atm together with radiotherapy for the treatment of cancer |
| US20240226235A1 (en) * | 2019-11-05 | 2024-07-11 | Acceleron Pharma Inc. | Treatments for systemic sclerosis |
| EP4073124A4 (en) * | 2019-12-11 | 2024-01-24 | Wuxi Biologics Ireland Limited | BIFUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGFBETA |
| KR20220118514A (ko) * | 2019-12-20 | 2022-08-25 | 아레스 트레이딩 에스.아. | IgG:TGF베타RII 융합 단백질 조성물 |
| CN111118064B (zh) * | 2019-12-24 | 2022-10-25 | 华南理工大学 | 一种精子生成障碍动物模型及其制备方法与应用 |
| WO2021142448A2 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock,Inc. | Tgf-beta inhibitors and use thereof |
| TW202135862A (zh) | 2020-01-11 | 2021-10-01 | 美商供石公司 | TGFβ抑制劑及其用途 |
| CN115135675A (zh) * | 2020-02-18 | 2022-09-30 | 南京金斯瑞生物科技有限公司 | 融合蛋白及其用途 |
| CN115175942B (zh) * | 2020-02-25 | 2025-05-30 | 上海药明生物技术有限公司 | 一种双功能融合蛋白及其用途 |
| WO2022011256A1 (en) | 2020-07-10 | 2022-01-13 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| WO2022063193A1 (zh) * | 2020-09-24 | 2022-03-31 | 上海齐鲁制药研究中心有限公司 | 同时靶向PD-L1和TGFβ的双功能分子及其医药用途 |
| CN116981485A (zh) | 2021-03-08 | 2023-10-31 | 南京金斯瑞生物科技有限公司 | 使用双重病毒载体系统递送抗体 |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| KR20240101664A (ko) * | 2021-11-19 | 2024-07-02 | 메뤼스 엔.페. | Pd-1 및 tgf-brii 결합 도메인을 포함하는 다중특이성 결합 모이어티 |
| WO2024187051A1 (en) | 2023-03-07 | 2024-09-12 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5785682A (en) * | 1995-03-22 | 1998-07-28 | Abbott Laboratories | Pre-filled syringe drug delivery system |
| IL323000A (en) * | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| US20130110045A1 (en) * | 2011-10-31 | 2013-05-02 | Ming-Yuan Wu | Single use intravenous therapy administering device with needle safety covers |
| ES2938182T3 (es) * | 2012-04-30 | 2023-04-05 | Biocon Ltd | Proteínas de fusión dirigidas/inmunomoduladoras y métodos de preparación de las mismas |
| WO2014193898A1 (en) * | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| AU2015213988B2 (en) * | 2014-02-10 | 2019-07-11 | Merck Patent Gmbh | Targeted TGFbeta inhibition |
| EP3206711B1 (en) * | 2014-10-14 | 2023-05-31 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| US10828353B2 (en) * | 2015-01-31 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| EP3277716B1 (en) * | 2015-04-03 | 2020-06-24 | XOMA Technology Ltd. | Treatment of cancer using inhibitors of tgf-beta and pd-1 |
| PT3294770T (pt) * | 2015-05-12 | 2020-12-04 | Hoffmann La Roche | Métodos terapêuticos e diagnósticos para o cancro |
-
2018
- 2018-01-05 RU RU2019124875A patent/RU2019124875A/ru unknown
- 2018-01-05 CA CA3048646A patent/CA3048646A1/en active Pending
- 2018-01-05 EP EP18736497.1A patent/EP3565599A4/en active Pending
- 2018-01-05 CN CN201880006085.0A patent/CN110198738A/zh active Pending
- 2018-01-05 BR BR112019013924-9A patent/BR112019013924A2/pt not_active Application Discontinuation
- 2018-01-05 KR KR1020197022795A patent/KR20190102059A/ko not_active Ceased
- 2018-01-05 MX MX2019008001A patent/MX2019008001A/es unknown
- 2018-01-05 WO PCT/US2018/012604 patent/WO2018129331A1/en not_active Ceased
- 2018-01-05 SG SG11201906157YA patent/SG11201906157YA/en unknown
- 2018-01-05 JP JP2019536228A patent/JP2020514290A/ja active Pending
- 2018-01-05 AU AU2018205233A patent/AU2018205233A1/en not_active Abandoned
-
2019
- 2019-07-02 US US16/460,792 patent/US20190330375A1/en not_active Abandoned
- 2019-07-03 PH PH12019501574A patent/PH12019501574A1/en unknown
- 2019-07-04 IL IL267856A patent/IL267856A/en unknown
- 2019-07-05 CL CL2019001871A patent/CL2019001871A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190330375A1 (en) | 2019-10-31 |
| JP2020514290A (ja) | 2020-05-21 |
| CN110198738A (zh) | 2019-09-03 |
| WO2018129331A1 (en) | 2018-07-12 |
| RU2019124875A3 (enExample) | 2021-07-08 |
| AU2018205233A1 (en) | 2019-07-11 |
| MX2019008001A (es) | 2019-09-09 |
| EP3565599A1 (en) | 2019-11-13 |
| CL2019001871A1 (es) | 2019-12-13 |
| EP3565599A4 (en) | 2020-07-01 |
| SG11201906157YA (en) | 2019-08-27 |
| IL267856A (en) | 2019-09-26 |
| KR20190102059A (ko) | 2019-09-02 |
| PH12019501574A1 (en) | 2019-11-04 |
| CA3048646A1 (en) | 2018-07-12 |
| BR112019013924A2 (pt) | 2020-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019124875A (ru) | Схемы дозирования и лекарственные формы для направленного ингибирования tgf-b | |
| RU2019124995A (ru) | Улучшенная теплопередача во время процедур абляции | |
| RU2017113700A (ru) | Способы изготовления орошаемого катетера с электродным узлом с гибкой схемой | |
| ATE507870T1 (de) | Transseptale/transmyokardiale ventrikuläre pacing-ableitung | |
| JP2006509547A (ja) | 血液動態パラメータをモニタリングおよび治療する方法およびシステム | |
| RU2015153896A (ru) | Баллон для абляции вокруг легочных вен | |
| JP2019531118A5 (enExample) | ||
| CN102939066A (zh) | 电极装置 | |
| RU2015156052A (ru) | Катетер с орошаемым точечным электродом с пористой подложкой и поверхностными микроэлектродами высокой плотности | |
| US20070224572A1 (en) | Device for Stimulating Gum Using Low Frequency | |
| JP2013521040A5 (enExample) | ||
| JP2018535017A (ja) | 早漏または勃起不全の治療用の経皮的筋肉電気刺激装置およびその使用方法 | |
| RU2019115684A (ru) | Улучшенная теплопередача через кончик катетера | |
| JP7568710B2 (ja) | 接触システムおよび接触システムの使用 | |
| US1740240A (en) | Cataphoric electrode | |
| JP2022504901A (ja) | 分離型密閉カバーを備える体腔挿入型超音波装置 | |
| EA201890902A1 (ru) | Микроэлектрод, предотвращающий кровоизлияние | |
| US6616656B2 (en) | Two-electrode endoscopic implement | |
| WO2009126383A3 (en) | Methods and apparatus for electrical treatment using balloon and electrode | |
| US20070043348A1 (en) | Instrument for the unipolar ablation of heart tissue | |
| KR101304423B1 (ko) | 전극침 및 그 제조 방법, 및 이를 포함하는 심부 국소 치료 장치 | |
| KR100634970B1 (ko) | 잇몸전용 저주파자극기 | |
| KR100972220B1 (ko) | 전기자극치료기용 도자컵 패드 | |
| CN201253417Y (zh) | 带驻留理疗贴的皮肤电极 | |
| JP3200213U (ja) | 複合機能を備えた電極パッチ |